{"id":6913,"date":"2023-09-06T12:00:00","date_gmt":"2023-09-06T12:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/"},"modified":"2023-09-06T12:00:00","modified_gmt":"2023-09-06T12:00:00","slug":"nanexa-presenterar-vid-ispor-europe-2023","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/","title":{"rendered":"Nanexa presenterar vid ISPOR Europe 2023"},"content":{"rendered":"
\n

Nanexa AB meddelar idag att bolaget f\u00e5tt ett vetenskapligt abstract accepterat till den internationella h\u00e4lsoekonomiska kongressen ISPOR Europe 2023, den 12:e-15:e November i K\u00f6penhamn, Danmark. Abstractet har titeln \u201cAssociation between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search\u201d och har blivit accepterat som en muntlig podium-presentation.<\/strong><\/p>\n<\/div>\n

\n

\u201dDet \u00e4r mycket gl\u00e4djande att vi f\u00e5tt detta abstract accepterat p\u00e5 en internationell h\u00e4lsoekonomisk vetenskaplig kongress av den h\u00e4r digniteten\u201d, s\u00e4ger Bengt Gustavsson, Director of Clinical Development and Medical Affairs p\u00e5 Nanexa. \u201dEn s\u00e5 kallad Systematic Literature Review \u00e4r alltid en av de grundstenar man bygger sin h\u00e4lsoekonomiska strategi p\u00e5. Denna strategi leder i sin tur fram till den prismodell man anv\u00e4nder sig av vid kommande prisf\u00f6rhandlingar med betalare i olika l\u00e4nder. V\u00e5ra data visar dels att f\u00f6ljsamheten till l\u00e4kemedelsbehandling mot multipelt myelom inte alltid \u00e4r s\u00e5 god som f\u00f6rv\u00e4ntat, dels att mer forskning beh\u00f6vs inom just detta omr\u00e5de och dels att det finns ett behov av en l\u00e5ngtidsverkande produkt som NEX-20 som kan f\u00f6rb\u00e4ttra f\u00f6ljsamheten av behandlingen.\u201d<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa presenterar vid ISPOR Europe 2023<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag att bolaget f\u00e5tt ett vetenskapligt abstract accepterat till den internationella h\u00e4lsoekonomiska kongressen ISPOR Europe 2023, den 12:e-15:e November i K\u00f6penhamn, Danmark. Abstractet har titeln \u201cAssociation between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search\u201d och har blivit accepterat som en muntlig podium-presentation.<\/p>\n","protected":false},"template":"","class_list":["post-6913","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa presenterar vid ISPOR Europe 2023 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa presenterar vid ISPOR Europe 2023 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att bolaget f\u00e5tt ett vetenskapligt abstract accepterat till den internationella h\u00e4lsoekonomiska kongressen ISPOR Europe 2023, den 12:e-15:e November i K\u00f6penhamn, Danmark. Abstractet har titeln \u201cAssociation between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search\u201d och har blivit accepterat som en muntlig podium-presentation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-presenterar-vid-ispor-europe-2023\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-presenterar-vid-ispor-europe-2023\\\/\",\"name\":\"Nanexa presenterar vid ISPOR Europe 2023 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-09-06T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-presenterar-vid-ispor-europe-2023\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-presenterar-vid-ispor-europe-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-presenterar-vid-ispor-europe-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa presenterar vid ISPOR Europe 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa presenterar vid ISPOR Europe 2023 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa presenterar vid ISPOR Europe 2023 - Nanexa AB","og_description":"Nanexa AB meddelar idag att bolaget f\u00e5tt ett vetenskapligt abstract accepterat till den internationella h\u00e4lsoekonomiska kongressen ISPOR Europe 2023, den 12:e-15:e November i K\u00f6penhamn, Danmark. Abstractet har titeln \u201cAssociation between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search\u201d och har blivit accepterat som en muntlig podium-presentation.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/","name":"Nanexa presenterar vid ISPOR Europe 2023 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-09-06T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-presenterar-vid-ispor-europe-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa presenterar vid ISPOR Europe 2023"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}